JP2019531288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531288A5 JP2019531288A5 JP2019514710A JP2019514710A JP2019531288A5 JP 2019531288 A5 JP2019531288 A5 JP 2019531288A5 JP 2019514710 A JP2019514710 A JP 2019514710A JP 2019514710 A JP2019514710 A JP 2019514710A JP 2019531288 A5 JP2019531288 A5 JP 2019531288A5
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- composition
- replication
- functional group
- defective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 15
- 239000013603 viral vector Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 10
- 125000000524 functional group Chemical group 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 3
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 1
- 241001068295 Replication defective viruses Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940023867 prime-boost vaccine Drugs 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000000352 supercritical drying Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16189276 | 2016-09-16 | ||
| EP16189276.5 | 2016-09-16 | ||
| PCT/EP2017/073370 WO2018050872A1 (en) | 2016-09-16 | 2017-09-15 | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531288A JP2019531288A (ja) | 2019-10-31 |
| JP2019531288A5 true JP2019531288A5 (cg-RX-API-DMAC10.html) | 2020-07-30 |
| JP7051132B2 JP7051132B2 (ja) | 2022-04-11 |
Family
ID=57083083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514710A Active JP7051132B2 (ja) | 2016-09-16 | 2017-09-15 | ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11166915B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3512939B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7051132B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN109952372A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018050872A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| EP3512939B1 (en) | 2016-09-16 | 2026-06-17 | Leukocare AG | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
| WO2020023612A1 (en) * | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| CN112261871B (zh) | 2018-07-28 | 2022-05-17 | 韩国外泌体生技有限公司 | 用于使外排体冻干的方法 |
| KR102163806B1 (ko) * | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| KR102288367B1 (ko) * | 2018-11-15 | 2021-08-11 | 주식회사 바이오앱 | 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법 |
| CN112138153B (zh) * | 2019-06-28 | 2022-08-23 | 怡道生物科技(苏州)有限公司 | 一种重组带状疱疹疫苗组合物及其用途 |
| EP4013436A1 (en) | 2019-08-14 | 2022-06-22 | Leukocare Ag | Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy |
| EP4158004A2 (en) * | 2020-05-28 | 2023-04-05 | Lonza Ltd | Formulations for viral vectors |
| WO2023167868A2 (en) * | 2022-03-01 | 2023-09-07 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions comprising a recombinant neuraminidase and cpg oligonucleotide adjuvant, and uses thereof |
| EP4598572A1 (en) * | 2022-10-04 | 2025-08-13 | Emergent Product Development Gaithersburg Inc. | Novel vsv virus formulations |
| CN117065720B (zh) * | 2023-07-21 | 2025-08-22 | 湖南新九方科技有限公司 | 一种热解生物炭吸附材料及其制备方法和应用 |
| WO2025125222A1 (en) * | 2023-12-11 | 2025-06-19 | Leukocare Ag | Compositions comprising viruses, viral vectors or virus-like particles |
| CN119548638B (zh) * | 2025-01-21 | 2025-10-24 | 金宇保灵生物药品有限公司 | 一种活疫苗耐热保护剂及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3718889A1 (de) | 1987-06-05 | 1988-12-22 | Behringwerke Ag | Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| DE19508192A1 (de) | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| ES2932278T3 (es) | 2004-06-01 | 2023-01-17 | Genzyme Corp | Composiciones y métodos para prevenir la agregación del vector AAV |
| ES2395035T3 (es) | 2004-08-17 | 2013-02-07 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de la IL-1 |
| KR101357685B1 (ko) * | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| EP1834651A1 (en) * | 2006-03-15 | 2007-09-19 | Universiteit Gent | Compositions and methods for veterinary vaccination |
| EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
| GB0715723D0 (en) | 2007-08-11 | 2007-09-19 | Ark Therapeutics Ltd | Formulation |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| US7998488B2 (en) | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| EP2236520A1 (en) | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| ES2661215T3 (es) * | 2009-05-20 | 2018-03-28 | Aeras | Composiciones víricas; inmunógenas; secadas por pulverización; estables |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| US8557253B2 (en) | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
| CN102188701A (zh) * | 2010-03-12 | 2011-09-21 | 上海泽润生物科技有限公司 | 一种磷酸铝佐剂及其制备方法 |
| JP5798356B2 (ja) | 2011-04-06 | 2015-10-21 | 一般財団法人化学及血清療法研究所 | 新規インフルエンザワクチン安定化剤 |
| RU2614257C2 (ru) | 2011-04-20 | 2017-03-24 | Сандоз Аг | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc |
| KR102049988B1 (ko) * | 2011-06-24 | 2019-11-28 | 머크 샤프 앤드 돔 코포레이션 | 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법 |
| EP3744833A1 (en) * | 2011-06-28 | 2020-12-02 | Leukocare Ag | Stabilisation method for viruses |
| CN103649105A (zh) | 2011-06-28 | 2014-03-19 | 白血球保健股份有限公司 | 防止(多)肽解折叠和/或诱导(多)肽(再)折叠的方法 |
| SI2766397T1 (sl) | 2011-10-11 | 2018-09-28 | F. Hoffmann-La Roche Ag | Izboljšano sestavljanje bispecifičnih protiteles |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| AU2013280480B2 (en) | 2012-06-25 | 2018-03-15 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| BR112015017307A2 (pt) | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
| JP6208866B2 (ja) | 2013-07-11 | 2017-10-04 | サイノファーム タイワン，リミティド | 硫酸化オリゴ糖を検出する分析法 |
| WO2015040234A1 (en) | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| CN105636609A (zh) * | 2013-10-25 | 2016-06-01 | 白血球保健股份有限公司 | 一种新颖的生产稳定疫苗的方法 |
| CN105039358B (zh) * | 2013-12-03 | 2020-02-28 | 北京康乐卫士生物技术股份有限公司 | 58型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| EP3119412A1 (en) | 2014-03-21 | 2017-01-25 | Boreal Invest | Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates |
| US10517943B2 (en) | 2014-12-01 | 2019-12-31 | Transgene S.A. | Stable liquid vaccinia virus formulations |
| EP3512939B1 (en) | 2016-09-16 | 2026-06-17 | Leukocare AG | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| US20190216925A1 (en) | 2016-09-16 | 2019-07-18 | Leukocare Ag | A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing |
| WO2018050874A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method of producing a liquid biopharmaceutical drug product |
-
2017
- 2017-09-15 EP EP17772654.4A patent/EP3512939B1/en active Active
- 2017-09-15 CN CN201780070621.9A patent/CN109952372A/zh active Pending
- 2017-09-15 WO PCT/EP2017/073370 patent/WO2018050872A1/en not_active Ceased
- 2017-09-15 US US16/333,726 patent/US11166915B2/en active Active
- 2017-09-15 JP JP2019514710A patent/JP7051132B2/ja active Active
-
2021
- 2021-10-21 US US17/507,496 patent/US12350375B2/en active Active